Boyer & Corporon Wealth Management LLC increased its position in shares of Novartis AG (NYSE:NVS) by 0.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,193 shares of the company’s stock after acquiring an additional 213 shares during the period. Boyer & Corporon Wealth Management LLC’s holdings in Novartis were worth $3,576,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Novartis by 223.5% during the 4th quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock worth $981,607,000 after acquiring an additional 7,902,964 shares in the last quarter. Bank of America Corp DE lifted its stake in Novartis by 25.1% during the 4th quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock worth $776,909,000 after acquiring an additional 1,817,005 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Novartis by 2.5% during the 4th quarter. Fisher Asset Management LLC now owns 7,609,632 shares of the company’s stock worth $652,983,000 after acquiring an additional 184,555 shares in the last quarter. Boston Partners lifted its stake in Novartis by 26.1% during the 4th quarter. Boston Partners now owns 7,046,794 shares of the company’s stock worth $604,685,000 after acquiring an additional 1,459,845 shares in the last quarter. Finally, FMR LLC increased its holdings in Novartis by 441.6% during the 4th quarter. FMR LLC now owns 7,016,047 shares of the company’s stock worth $602,046,000 after purchasing an additional 5,720,650 shares during the period. 11.66% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have weighed in on NVS. JPMorgan Chase & Co. restated a “sell” rating on shares of Novartis in a report on Tuesday, January 29th. Morgan Stanley downgraded Novartis from an “equal weight” rating to an “underweight” rating and upped their price target for the stock from $82.50 to $82.52 in a report on Wednesday, April 10th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “strong sell” rating in a report on Thursday, April 11th. Liberum Capital upgraded Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Finally, Guggenheim upgraded Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target on the stock in a report on Wednesday, April 24th. Five investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $87.57.

Shares of NYSE NVS opened at $82.01 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. Novartis AG has a 1-year low of $63.60 and a 1-year high of $85.08. The stock has a market cap of $191.04 billion, a price-to-earnings ratio of 16.11, a P/E/G ratio of 1.99 and a beta of 0.66.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.10. Novartis had a return on equity of 16.75% and a net margin of 24.55%. The company had revenue of $11.11 billion for the quarter, compared to the consensus estimate of $11.76 billion. During the same quarter in the prior year, the business earned $1.28 EPS. Novartis’s revenue was up 1.7% on a year-over-year basis. On average, research analysts expect that Novartis AG will post 5 earnings per share for the current fiscal year.

WARNING: “Boyer & Corporon Wealth Management LLC Boosts Position in Novartis AG (NVS)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2019/05/21/boyer-corporon-wealth-management-llc-boosts-position-in-novartis-ag-nvs.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Article: What does a bar chart display?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.